Clinical trial
A Randomized Evaluation of Vinorelbine Versus Gemcitabine for Mobilization of Peripheral Stem Cells in Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
NCT02791373 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Evaluation of Vinorelbine Versus Gemcitabine for Mobilization of Peripheral Stem Cells in Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- December 31, 2017
- Enrollment
- 136 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.